Edward Kim
3 clinical trials · Sponsor
| Record | Firm | Date |
|---|---|---|
| BMS-986205 and Nivolumab as First or Second Line Therapy in Treating Patients With Liver Cancer (NCT03695250) | Edward Kim | 2018-10-16 |
Track Edward Kim automatically
Every clearance here is in the API, with alerts when new ones post.